面部骨折医院治疗的药物经济学方面——基于最近有社会和经济转型史的巴尔干国家数据的疾病成本研究

IF 0.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Jana Desnica, M. Kostić, S. Jankovic, Sara Mijailovic, K. Parezanović Ilić, O. Milovanović, D. Vulovic
{"title":"面部骨折医院治疗的药物经济学方面——基于最近有社会和经济转型史的巴尔干国家数据的疾病成本研究","authors":"Jana Desnica, M. Kostić, S. Jankovic, Sara Mijailovic, K. Parezanović Ilić, O. Milovanović, D. Vulovic","doi":"10.32383/appdr/157009","DOIUrl":null,"url":null,"abstract":"Background/purpose: The incidence of facial fractures has a tendency to rise, which positively correlates with increasing total costs of treating this medical condition. The aim of this study was to identify the total costs of the hospital treatment of facial fractures and to analyze its main determinants.\nMaterials and methods: This retrospective \"cost-of-illness\" study \"from bottom to the top\" approach was performed from the perspective of the Republic Health Insurance Fund. This study included 46 patients who were treated due to facial fractures at the Clinic for Maxillofacial Surgery at the Clinical Center Kragujevac in the period from the beginning of December 2017. to January 31, 2019.\nResults: The total costs of hospital treatment of all types of treated fractures amounted to 20,214.30€, and the average total cost per patient was estimated at 439.44±299.53€. The costs related to the length of hospitalization represented the largest part of the total direct costs, with a contribution of 31% and with a value of 6,329.30±80.18 €. \nConclusions: Results of this pilot study pointed out that the total costs of treating facial fractures in the socio-economic sphere of Balkan countries are lower than in other health care systems, mostly due to differences in valuing medical services compared to countries within the European Union. Due to the rising incidence of injuries and obligatory hospital treatment of these conditions, this kind of pharmacoeconomic evaluation could contribute to the introduction of new therapeutic strategies for adequate allocation of resources within health systems.","PeriodicalId":7147,"journal":{"name":"Acta poloniae pharmaceutica","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacoeconomic aspects of hospital treatment of facial fractures - cost of illness study based on data from Balkan country with recent history of social and economic transition\",\"authors\":\"Jana Desnica, M. Kostić, S. Jankovic, Sara Mijailovic, K. Parezanović Ilić, O. Milovanović, D. Vulovic\",\"doi\":\"10.32383/appdr/157009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/purpose: The incidence of facial fractures has a tendency to rise, which positively correlates with increasing total costs of treating this medical condition. The aim of this study was to identify the total costs of the hospital treatment of facial fractures and to analyze its main determinants.\\nMaterials and methods: This retrospective \\\"cost-of-illness\\\" study \\\"from bottom to the top\\\" approach was performed from the perspective of the Republic Health Insurance Fund. This study included 46 patients who were treated due to facial fractures at the Clinic for Maxillofacial Surgery at the Clinical Center Kragujevac in the period from the beginning of December 2017. to January 31, 2019.\\nResults: The total costs of hospital treatment of all types of treated fractures amounted to 20,214.30€, and the average total cost per patient was estimated at 439.44±299.53€. The costs related to the length of hospitalization represented the largest part of the total direct costs, with a contribution of 31% and with a value of 6,329.30±80.18 €. \\nConclusions: Results of this pilot study pointed out that the total costs of treating facial fractures in the socio-economic sphere of Balkan countries are lower than in other health care systems, mostly due to differences in valuing medical services compared to countries within the European Union. Due to the rising incidence of injuries and obligatory hospital treatment of these conditions, this kind of pharmacoeconomic evaluation could contribute to the introduction of new therapeutic strategies for adequate allocation of resources within health systems.\",\"PeriodicalId\":7147,\"journal\":{\"name\":\"Acta poloniae pharmaceutica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta poloniae pharmaceutica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.32383/appdr/157009\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta poloniae pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32383/appdr/157009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:面部骨折的发生率有上升趋势,这与治疗这种疾病的总费用增加呈正相关。本研究的目的是确定医院治疗面部骨折的总费用,并分析其主要决定因素。材料和方法:这项回顾性的“疾病成本”研究“自下而上”的方法是从共和国健康保险基金的角度进行的。本研究纳入了2017年12月初在克拉古耶瓦茨临床中心颌面外科诊所因面部骨折接受治疗的46例患者。至2019年1月31日。结果:所有类型骨折的住院总费用为20214.30€,每例患者的平均总费用为439.44±299.53€。与住院时间长短有关的费用占直接费用总额的最大部分,占31%,价值为6 329.30±80.18欧元。结论:这项试点研究的结果指出,在巴尔干国家的社会经济领域,治疗面部骨折的总成本低于其他医疗保健系统,主要是由于与欧盟国家相比,医疗服务的价值不同。由于伤害发生率的上升和这些情况的强制性住院治疗,这种药物经济学评价可以有助于引入新的治疗策略,以充分分配卫生系统内的资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacoeconomic aspects of hospital treatment of facial fractures - cost of illness study based on data from Balkan country with recent history of social and economic transition
Background/purpose: The incidence of facial fractures has a tendency to rise, which positively correlates with increasing total costs of treating this medical condition. The aim of this study was to identify the total costs of the hospital treatment of facial fractures and to analyze its main determinants. Materials and methods: This retrospective "cost-of-illness" study "from bottom to the top" approach was performed from the perspective of the Republic Health Insurance Fund. This study included 46 patients who were treated due to facial fractures at the Clinic for Maxillofacial Surgery at the Clinical Center Kragujevac in the period from the beginning of December 2017. to January 31, 2019. Results: The total costs of hospital treatment of all types of treated fractures amounted to 20,214.30€, and the average total cost per patient was estimated at 439.44±299.53€. The costs related to the length of hospitalization represented the largest part of the total direct costs, with a contribution of 31% and with a value of 6,329.30±80.18 €. Conclusions: Results of this pilot study pointed out that the total costs of treating facial fractures in the socio-economic sphere of Balkan countries are lower than in other health care systems, mostly due to differences in valuing medical services compared to countries within the European Union. Due to the rising incidence of injuries and obligatory hospital treatment of these conditions, this kind of pharmacoeconomic evaluation could contribute to the introduction of new therapeutic strategies for adequate allocation of resources within health systems.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
74
审稿时长
6-12 weeks
期刊介绍: The international journal of the Polish Pharmaceutical Society is published in 6 issues a year. The journal offers Open Access publication of original research papers, short communications and reviews written in English, in all areas of pharmaceutical sciences. The following areas of pharmaceutical sciences are covered: Analysis, Biopharmacy, Drug Biochemistry, Drug Synthesis, Natural Drugs, Pharmaceutical Technology, Pharmacology and General. A bimonthly appearing in English since 1994, which continues “Acta Poloniae Pharmaceutica”, whose first issue appeared in December 1937. The war halted the activity of the journal’s creators. Issuance of “Acta Poloniae Pharmaceutica” was resumed in 1947. From 1947 the journal appeared irregularly, initially as a quarterly, then a bimonthly. In the years 1963 – 1973 alongside the Polish version appeared the English edition of the journal. Starting from 1974 only works in English are published in the journal. Since 1995 the journal has been appearing very regularly in two-month intervals (six books a year). The journal publishes original works from all fields of pharmacy, summaries of postdoctoral dissertations and laboratory notes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信